Human DCC Antibody
R&D Systems, part of Bio-Techne | Catalog # AF5884
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Sheep IgG
Product Specifications
Immunogen
E. coli-derived recombinant human DCC
Ser1323-Phe1447
Accession # P43146
Ser1323-Phe1447
Accession # P43146
Specificity
Detects human DCC in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) ICAM‑1, rhICAM-2, rhICAM-3, rhMadCAM-1, rhPECAM-1, rhVCAM-1, and rhCEACAM-1 is observed.
Clonality
Polyclonal
Host
Sheep
Isotype
IgG
Scientific Data Images for Human DCC Antibody
Detection of Human DCC by Western Blot.
Western blot shows lysates of SH-SY5Y human neuroblastoma cell line and HT-29 human colon adenocarcinoma cell line. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human DCC Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5884) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for DCC at approximately 190 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.Applications for Human DCC Antibody
Application
Recommended Usage
Western Blot
1 µg/mL
Sample: SH-SY5Y human neuroblastoma cell line and HT-29 human colon adenocarcinoma cell line
Sample: SH-SY5Y human neuroblastoma cell line and HT-29 human colon adenocarcinoma cell line
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: DCC
Deleted in colorectal cancer (DCC) is a 170-190 kDa transmembrane glycoprotein that contains four Ig-like domains and six fibronectin type III repeats in its extracellular domain. DCC is expressed on axons during development where its binding to Netrin-1 regulates axon migration and myelination. It inhibits apoptosis when bound by Netrin-1 and can induce apoptosis in the absence of ligand. DCC also functions as an adhesion molecule and a tumor suppressor on intestinal epithelial cells. Deficiencies in DCC function are associated with the development and metastasis of many tumors. Within aa 1323-1447 of the cytoplasmic domain, human DCC shares 98% aa sequence identity with the mouse and rat DCC.
Long Name
Deleted in Colorectal Cancer
Alternate Names
Colorectal cancer suppressor, CRC18, CRCR1, deleted in colorectal cancer protein, deleted in colorectal carcinoma, IGDCC1colorectal tumor suppressor, Immunoglobulin superfamily DCC subclass member 1, immunoglobulin superfamily, DCC subclass, member 1, netrin receptor DCC, Tumor suppressor protein DCC
Gene Symbol
DCC
UniProt
Additional DCC Products
Product Documents for Human DCC Antibody
Product Specific Notices for Human DCC Antibody
This product or the use of this product is covered by U.S. Patents owned by The Regents of the University of California. This product is for research use only and is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic, therapeutic or drug discovery purposes is prohibited. In order to obtain alicense to use this product for such purposes, contact The Regents of the University of California.
U.S. Patent # 5,939,271, 6,277,585, and other U.S. and international patents pending.
For research use only
Loading...
Loading...
Loading...
Loading...